Neurosense Therapeutics is trading 7.98% down at $2.83, with no verified company-specific catalyst tied to the decline.
- An October 19 headline reported a U.S. patent application for traumatic brain injury, but available coverage provides no details or evidence linking it to the selloff.
- The supplied market snapshot shows the Nasdaq higher, so broad-market weakness does not clearly explain the move. Trading activity details are unavailable.